Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Divesiran - Silence Therapeutics

Next Previous
X
Search
Drug Profile

Divesiran - Silence Therapeutics

Alternative Names: SLN-124

Latest Information Update: 03 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intradigm Corporation
  • Developer Silence Therapeutics
  • Class Antineoplastics; Hexosamines; Small interfering RNA
  • Mechanism of Action RNA interference; TMPRSS6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera; Myelodysplastic syndromes; Beta-thalassaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Polycythaemia vera
  • Phase I Myelodysplastic syndromes
  • No development reported Haemochromatosis; Iron overload
  • Discontinued Beta-thalassaemia

Most Recent Events

  • 27 Jun 2024 Efficacy, adverse events and pharmacodynamics data from a phase I/II clinical trials in Polycythaemia vera released by Silence Therapeutics
  • 14 Nov 2023 Discontinued - Phase-I for Beta-thalassaemia in Bulgaria (SC)
  • 14 Nov 2023 Discontinued - Phase-I for Beta-thalassaemia in Germany (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top